STAT3 and neoplasm: Moreover, Yan et al. provided strong evidence of the anti-tumor effect of JAK inhibitor AZD1480 in NB, RMS, and ES family tumors, indicating that downregulation of the JAK/STAT3 pathway could be beneficial for these patients [98].